Diabetic Kidney Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Diabetic Kidney Disease Market Outlook

Thelansis’s “Diabetic Kidney Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Kidney Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Kidney Disease Overview

Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease (ESKD), affecting approximately 40% of patients with type 1 and 2 diabetes. Diabetic nephropathy is the primary cause of kidney disease in patients who require renal replacement therapy. The exact cause of diabetic nephropathy remains unknown; however, insulin resistance, genetics, hyperglycemia, and autoimmune processes may contribute. Hyperglycemia causes the production of reactive oxygen species, which activate various pathways, including protein kinase C, hexosamine, polyol, and advanced glycation end products (AGE). The resulting inflammation is characterized by increased levels of cytokines and chemokines such as IL-6, MCP-1, TGF-beta, and VEGF, leading to fibrosis, inflammation, and increased vascular permeability. Chronic tubular injury and fibrosis occur as a result of epithelial-mesenchymal cell transformation. Albuminuria results from podocytopathy, and proteinuria occurs due to systemic and intraglomerular hypertension. Proteinuria is a hallmark of diabetic nephropathy, and the absence of retinopathy makes diabetic nephropathy less likely in type 1 diabetes mellitus (T1DM) patients. Diabetic nephropathy patients risk developing acute kidney injury, and microalbuminuria is an independent risk factor for cardiovascular mortality. Most patients die from end-stage renal disease, and diabetic retinopathy is often associated with diabetic nephropathy. The prevalence of DKD in most type 2 diabetics – at any point in time – is approximately 30%-50%, and it was reported among US diabetic adults (>90% type 2).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Diabetic Kidney Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034